EIF4A1 and cancer: Our findings using the pharmacological eIF4Ai CR-1-13-1-B in the chemoresistant MOLM-14 model of AML are consistent with the pleotropic effects of the mTORC1/eIF4F/eIF4A axis in promoting bioenergetic and anti-apoptotic programs in cancer cells and uncover a key role of eIF4A in facilitating metabolic rewiring and maintaining mitochondrial homeostasis and bioenergetics.